Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Consensus Target Price from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $17.25.

ENTA has been the subject of a number of research analyst reports. Robert W. Baird cut their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. JMP Securities reissued a “market outperform” rating and set a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Finally, HC Wainwright decreased their price target on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, December 24th.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.64% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its stake in Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after acquiring an additional 85,082 shares in the last quarter. Barclays PLC lifted its position in shares of Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 20,478 shares in the last quarter. Geode Capital Management LLC grew its position in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after purchasing an additional 14,575 shares in the last quarter. Krensavage Asset Management LLC increased its stake in Enanta Pharmaceuticals by 19.7% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after buying an additional 246,736 shares during the period. Finally, Wellington Management Group LLP acquired a new position in Enanta Pharmaceuticals in the 3rd quarter valued at approximately $360,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $5.75 on Thursday. Enanta Pharmaceuticals has a 12 month low of $5.30 and a 12 month high of $17.80. The firm has a market capitalization of $121.87 million, a PE ratio of -1.05 and a beta of 0.49. The company’s 50 day simple moving average is $8.72 and its 200 day simple moving average is $11.32.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.33) earnings per share. Sell-side analysts anticipate that Enanta Pharmaceuticals will post -4.73 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.